

MURAE ORGANISOR LIMITED

(Formerly known as Earum Pharmaceuticals Limited)

CIN: L24230GJ2012PLC071299

Regd. Office: A-1311, Sun West Bank, Ashram Road, Ahmedabad, Gujarat – 380 009

E-mail: earumpharma@gmail.com Website: www.earumpharma.com

Date: 14th August, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001

Dear Sir/ Madam,

**Sub: Statement of Deviation or Variation of funds under Regulation 32 of SEBI
(Listing Obligations and Disclosure Requirements) Regulations, 2015**

Ref: Security Id: MURAE / Code: 542724

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Section III-C of SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, we hereby confirm that there are no deviation(s) or variation(s) in respect of the utilization of the proceeds received in one or more tranches on the allotment of 44,99,99,998 Convertible Warrants on a preferential basis during the Quarter ended on 30th June, 2024.

A statement confirming that there is no deviation or variation in the utilization of these proceeds is enclosed herewith.

This is for your information and records please.

Thanking You.

For, Murae Organisor Limited
(Formerly known as Earum Pharmaceuticals Limited)

Manthan Tilva
Managing Director
DIN: 10453462

MURAE ORGANISOR LIMITED

(Formerly known as Earum Pharmaceuticals Limited)

CIN: L24230GJ2012PLC071299

Regd. Office: A-1311, Sun West Bank, Ashram Road, Ahmedabad, Gujarat – 380 009

E-mail: earumpharma@gmail.com Website: www.earumpharma.com

Annexure A

STATEMENT OF DEVIATION OR VARIATION IN UTILIZATION OF FUNDS RAISED

Name of listed entity	Murae Organisor Limited
Mode of Fund Raising	Preferential Issue – Convertible Warrants
Date of Raising Funds	29 th May, 2024 and 29 th June, 2024
Amount Raised	Allotment of 44,99,99,998 convertible warrants, each convertible into one equity shares of face value of Rs. 2 each upon receipt of Warrant Subscription Price at the rate of Rs. 2.20/- per warrant, Rs. 24,74,99,999.50/- being 25% of the total consideration and Rs. 26,75,00,000/- being 27.02% of total consideration (receipt of 2nd Tranche).
Report filed for Quarter ended	30-06-2024
Monitoring Agency	Not Applicable
Monitoring Agency Name, if applicable	Not Applicable
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the Unit holders	Not Applicable
If Yes, Date of Unit holders Approval	Not Applicable
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	None
Comments of the auditors, if any	None

1. Set forth below are objects for which funds have been raised and where there has been a deviation, in the following table for Consideration received on 29th May, 2024:

Original Object	Modified Object, if any	Original Allocation (₹ in Lakh) *	Modified Allocation, if any	Funds Utilised (₹ in Lakh)	Amount of Deviation/ Variation for Quarter according to applicable object	Remarks if any
To Meet Working Capital Requirements	No	1881.00	-	1881.00	Nil	NA
General Corporate Purpose	No	594.00	-	594.00	Nil	NA

*25% of total consideration received on Board Meeting held on 29th May, 2024.

MURAE ORGANISOR LIMITED

(Formerly known as Earum Pharmaceuticals Limited)

CIN: L24230GJ2012PLC071299

Regd. Office: A-1311, Sun West Bank, Ashram Road, Ahmedabad, Gujarat – 380 009

E-mail: earumpharma@gmail.com Website: www.earumpharma.com

2. Set forth below are objects for which funds have been raised and where there has been a deviation, in the following table for Consideration received on 29th June, 2024:

Original Object	Modified Object, if any	Original Allocation (₹ in Lakh) *	Modified Allocation, if any	Funds Utilised (₹ in Lakh)	Amount of Deviation/ Variation for Quarter according to applicable object	Remarks if any
To Meet Working Capital Requirements	No	2033.00	-	2033.00	Nil	NA
General Corporate Purpose	No	642.00	-	642.00	Nil	NA

* 27.02% of consideration received on Board Meeting held on 29th June, 2024.

Deviation or variation could mean:

- Deviation in the objects or purposes for which the funds have been raised or
- Deviation in the amount of funds actually utilized as against what was originally disclosed or
- Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc.

For, Murae Organisor Limited

(Formerly known as Earum Pharmaceuticals Limited)

Manthan Tilva
Managing Director
DIN: 10453462